The association between APOE allele variants and inflammatory markers in a large-scale Chinese population Authors: Boyang Zeng, Cong Ma, Shuaishuai Zhang, Jiaojiao Qiu, Yue Chen, Nan Zhang, Qinzhi Cao, Yan Wang, Zimei Chi, Qinan Wu, Jin Sun, Guanchao Sun, Bangguo Qin, Man Li, Bokai Cheng, Qiligeer Bao, Shuang Cai, Meiqi Cong, Guangwei Luo, Ping Zhu, Shuxia Wang Published: 2025 ABSTRACT PurposeCurrent evidence suggests that apolipoprotein E (APOE) is associated with lipid metabolism, cardiovascular diseases, and neurodegenerative disorders. However, the physiological pathways of APOE-mediated inflammation remain incompletely elucidated, and a specific inflammatory marker that captures the pro-inflammatory activity of the APOE ε4 allele remains elusive. As a composite peripheral blood biomarker, Systemic immune-inflammation index (SII) is a novel marker of inflammation. This study aimed to investigate the association between APOE alleles and Systemic Immune-Inflammation Index.Patients and methodsA total of 13,926 participants (9,098 males and 4,828 females) were recruited from The People’s Liberation Army General Hospital (November 2017 to July 2019). APOE alleles (ε2, ε3, and ε4) were determined by genotyping rs429358 and rs7412 SNPs. SII was calculated as (platelet count × neutrophil count)/lymphocyte count. Multivariable linear regression models (adjusted for demographics, lifestyle, and clinical covariates) and subgroup analyses were performed to assess the APOE-SII associations, with ε3 as the reference.ResultsThe frequencies of APOE alleles ɛ3, ɛ2, and ɛ4 were70.7%, 13.8%, and 15.5% respectively in 13,926 Chinese patients. The mean SII was lower in ɛ2 carriers than in ɛ3 (373.74*10^9/L vs. 403.53*10^9/L, p < 0.001), and higher in ɛ4 carriers (430.22*10^9/L, p < 0.001). APOE ε4 carriers showed a significantly elevated SII versus ε3 in all models (β = 0.059, 95% CI: 0.041–0.077, p < 0.05), independent of the covariates. Conversely, ε2 carriers exhibited a reduced SII (β=-0.077, 95% CI: -0.096 to -0.058, p < 0.05). The SII correlated significantly with the APOE gene in subgroups stratified by sex, age, hypertension, and diabetes (p < 0.05).ConclusionAPOE contributes to elevated disease risk by inducing a state of chronic low-grade inflammation, resulting from modulation of both adaptive and innate immune responses. Introduction Apolipoprotein E (APOE) is a structural component of chylomicrons, which is encoded by the APOE gene, located in chromosome 19, q13.32, constituting three common alleles (ε2, ε3, and ε4) [1]. APOE ε4 predisposes to cerebrovascular and neurological diseases via mechanisms involving dysregulated lipid metabolism, enhanced inflammation, endothelial dysfunction, and impaired vascular structure and stability [2]. The combined effects of APOE ε4-driven instability, oxidative stress, mitochondrial dysfunction, and blood-brain barrier disruption drive immune cells into a chronically activated, dysfunctional state, resulting in a self-perpetuating inflammatory cycle through sustained pro-inflammatory cytokine release [3]. However, traditional inflammatory markers such as high-sensitivity C-reactive protein (Hs-CRP), primarily derived from the liver in response to systemic acute-phase reactions following tissue injury or infection, may be insufficient to characterize the chronic, low-grade, and innate immune cell-predominant inflammatory processes driven by the APOE ε4 allele within specific tissues such as the brain parenchyma and vascular walls [4, 5]. This cell-mediated immune dysregulation is considered a critical bridge linking the genotype to clinical phenotypes. Notably, this inflammatory pattern aligns closely with the concept of “inflammaging” in aging research, which refers to the progressive changes in immune function and a chronic, low-grade proinflammatory state that accompanies aging. It is hypothesized that the APOE ε4 allele may serve as an important genetic determinant of inter-individual heterogeneity in inflammaging, specifically exacerbating the inflammatory burden in neural and vascular systems [6]. To more accurately capture this process in circulation, we introduce the Systemic Immune-Inflammation Index (SII)—a composite metric integrating neutrophil, lymphocyte, and platelet counts [7]. SII directly reflects the dynamic balance of peripheral immune cells and is theoretically more sensitive to chronic, cell-mediated immune activation than Hs-CRP. However, current research on the association between different APOE alleles and SII is insufficient, and the effects of APOE alleles on inflammatory pathways may be heterogeneous. Therefore, we conducted a population-based cross-sectional study to explore the distribution characteristics of the APOE allele and the SII in a large-scale Chinese population. Materials and methods Participants A total of 22,739 individuals who underwent APOE gene testing at The First Medical Center of the People’s Liberation Army General Hospital between November 2017 and July 2019 were recruited (Fig. 1). A total of 4,067 patients had missing SII data. Exclusion criteria included: [1] Presence of other active malignancies; [2] Active infection or chronic active inflammatory diseases; [3] History of hematological diseases; [4] Severe hepatic dysfunction (Child-Pugh class B or C) or renal insufficiency (eGFR < 30 ml/min/1.73 m²); Ultimately, 13,926 patients (9,098 males and 4,828 females) were remained in the present study. Fig. 1Flowchart of participant selection Flowchart of participant selection APOE gene detection Genomic DNA was isolated from 2 ml peripheral blood using the MagNA Pure 96 DNA and Viral Nucleic Acid Small Volume Kit (Roche Diagnostics [Shanghai] Ltd., Shanghai, China) following the manufacturer’s protocol. Two SNPs in the APOE gene, rs429358 (ε4) and rs7412 (ε2), were identified using a SLCO1B1 and ApoE Gene Detection Kit (YZY Medical Science and Technology, Wuhan, Hubei, China). Polymerase chain reaction amplification was performed and the APOE gene chip assay was used to determine the genotypes. For genotyping quality control, blank tubes without DNA were included as negative controls for analysis, and 10% of the samples were repeatedly analyzed for confirmation. SII and covariates The SII was defined as follows: SII = P × N/L, where P, N, and L were the preoperative peripheral platelet, neutrophil, and lymphocyte counts, respectively [7]. Lymphocyte, neutrophil, and platelet counts were measured using an automatic hematology analysis device and reported as 10⁹ cells. Statistical analysis Continuous variables are expressed as mean (M) and standard deviation (SD), and categorical variables are expressed as proportions. Differences were evaluated using the analysis of variance or the t-test for continuous variables, and the chi-square test for categorical variables in SII, blood cells, platelets, and lipids among participants grouped by the APOE allele. Multivariable linear regression models were used to assess the association between the APOE genotype (with ε3 as the control) and the SII, with covariates adjusted for. Model 1 had no covariates; Model 2 was adjusted for sex, age, smoking, and drinking, and Model 3 was adjusted for sex, age, smoking, drinking, blood APOE concentration, hypertension, cardiovascular disease, diabetes and cerebral stroke. In the models, the regression coefficient β and 95% confidence interval (CI) were used to evaluate whether the SII levels of the different APOE alleles differed from those of ε3. Statistical analyses were performed using R Studio (version 4.4.1) and SPSS (version 27). Statistical significance was set at p < 0.05. Results Baseline characteristics of participants in the different APOE allele A total of 13,926 participants were included, 65.3% of whom were male, with a mean age of 50.0 years and a mean SII of 403.58 × 10⁹/L. The clinical characteristics of the participants grouped by the APOE allele are shown in Table 1. The frequencies of APOE alleles ɛ3, ɛ2, and ɛ4 were 70.7%, 13.8%, and 15.5% respectively. The mean SII was lower in ɛ2 carriers than in ɛ3 (373.74*10^9/L vs. 403.53*10^9/L, p < 0.001), and higher in ɛ4 carriers (430.22*10^9/L, p < 0.001). Statistically significant differences in TC, TG, LDL-C, HDL-C, and APOE concentrations were observed among the different AOPE alleles, which is consistent with the results of numerous previous studies. Table 1Baseline characteristics of participants in the different APOE allelesOverallN = 13,926E3N = 9,846(70.7%)E2N = 1,915(13.8%)E4N = 2,165(15.5%)P- valuesMale, n (%)9,098(65.3%)6,420(65.2%)1,225 (64.0%)1,453 (67.1%)0.097Age, M ± SD(years)50.0 ± 9.450.2 ± 9.349.9 ± 9.549.6 ± 9.50.032WBC, M ± SD(*10^9/L)5.82 ± 1.395.80 ± 1.395.74 ± 1.335.97 ± 1.42< 0.001NEU, M ± SD(*10^9/L)3.28 ± 0.983.27 ± 0.993.18 ± 0.893.43 ± 0.99< 0.001LYM, M ± SD(*10^9/L)1.98 ± 0.561.97 ± 0.562.01 ± 0.571.97 ± 0.570.029PLT, M ± SD(*10^9/L)232 ± 53232 ± 54226 ± 51237 ± 52< 0.001SII, M ± SD(*10^9/L)403.58 ± 162.35403.53 ± 165.38373.74 ± 139.43430.22 ± 162.75< 0.001Hs-CRP, M ± SD(mg/L)1.00 ± 0.691.02 ± 0.701.06 ± 0.690.84 ± 0.62< 0.001LDL-C, M ± SD(mmol/L)3.17 ± 0.903.21 ± 0.892.81 ± 0.843.32 ± 0.93< 0.001TC, M ± SD(mmol/L)4.70 ± 0.934.72 ± 0.924.46 ± 0.924.81 ± 0.92< 0.001TG, M ± SD(mmol/L)1.80 ± 1.261.75 ± 1.211.84 ± 1.381.95 ± 1.38< 0.001HDL-C, M ± SD(mmol/L)1.29 ± 0.371.29 ± 0.361.33 ± 0.381.24 ± 0.36< 0.001APOE, M ± SD(mg/L)5.4 ± 1.65.2 ± 1.46.6 ± 2.15.2 ± 1.6< 0.001Hypertension, n (%)3,848 (27.6%)2,573 (26.1%)449 (23.4%)826 (38.2%)< 0.001Cardiovascular disease, n (%)499 (3.6%)300 (3.0%)52 (2.7%)147 (6.8%)< 0.001Diabetes, n (%)1,937 (13.9%)1286 (13.1%)176 (12.1%)273 (19.1%)< 0.001Cerebral stroke, n (%)428 (3.1%)323 (3.3%)20 (1.0%)85 (3.9%)< 0.001Smoking, n (%)4,237 (30.4%)2.991 (30.4%)569 (29.7%)677 (31.3%)0.549Drinking, n (%)7,727 (55.5%)5.455 (55.4%)1,037 (54.2%)1,235 (57.0%)0.171Continuous variables were expressed as mean (M) with standard deviation (SD), and categorical variables were expressed as proportions. Differences were evaluated using the analysis of variance or the t-test for continuous variables, and the chi-square test for categorical variables. Statistical significance was set at p < 0.05LDL-C Low-density lipoprotein cholesterol, TC Total cholesterol, TG Triglyceride, HDL-C High-density lipoprotein cholesterol, APOE Blood APOE concentration, WBC Leukocyte, NEU Neutrophil, LYM Lymphocyte, PLT Platelet Table 1Baseline characteristics of participants in the different APOE allelesOverallN = 13,926E3N = 9,846(70.7%)E2N = 1,915(13.8%)E4N = 2,165(15.5%)P- valuesMale, n (%)9,098(65.3%)6,420(65.2%)1,225 (64.0%)1,453 (67.1%)0.097Age, M ± SD(years)50.0 ± 9.450.2 ± 9.349.9 ± 9.549.6 ± 9.50.032WBC, M ± SD(*10^9/L)5.82 ± 1.395.80 ± 1.395.74 ± 1.335.97 ± 1.42< 0.001NEU, M ± SD(*10^9/L)3.28 ± 0.983.27 ± 0.993.18 ± 0.893.43 ± 0.99< 0.001LYM, M ± SD(*10^9/L)1.98 ± 0.561.97 ± 0.562.01 ± 0.571.97 ± 0.570.029PLT, M ± SD(*10^9/L)232 ± 53232 ± 54226 ± 51237 ± 52< 0.001SII, M ± SD(*10^9/L)403.58 ± 162.35403.53 ± 165.38373.74 ± 139.43430.22 ± 162.75< 0.001Hs-CRP, M ± SD(mg/L)1.00 ± 0.691.02 ± 0.701.06 ± 0.690.84 ± 0.62< 0.001LDL-C, M ± SD(mmol/L)3.17 ± 0.903.21 ± 0.892.81 ± 0.843.32 ± 0.93< 0.001TC, M ± SD(mmol/L)4.70 ± 0.934.72 ± 0.924.46 ± 0.924.81 ± 0.92< 0.001TG, M ± SD(mmol/L)1.80 ± 1.261.75 ± 1.211.84 ± 1.381.95 ± 1.38< 0.001HDL-C, M ± SD(mmol/L)1.29 ± 0.371.29 ± 0.361.33 ± 0.381.24 ± 0.36< 0.001APOE, M ± SD(mg/L)5.4 ± 1.65.2 ± 1.46.6 ± 2.15.2 ± 1.6< 0.001Hypertension, n (%)3,848 (27.6%)2,573 (26.1%)449 (23.4%)826 (38.2%)< 0.001Cardiovascular disease, n (%)499 (3.6%)300 (3.0%)52 (2.7%)147 (6.8%)< 0.001Diabetes, n (%)1,937 (13.9%)1286 (13.1%)176 (12.1%)273 (19.1%)< 0.001Cerebral stroke, n (%)428 (3.1%)323 (3.3%)20 (1.0%)85 (3.9%)< 0.001Smoking, n (%)4,237 (30.4%)2.991 (30.4%)569 (29.7%)677 (31.3%)0.549Drinking, n (%)7,727 (55.5%)5.455 (55.4%)1,037 (54.2%)1,235 (57.0%)0.171Continuous variables were expressed as mean (M) with standard deviation (SD), and categorical variables were expressed as proportions. Differences were evaluated using the analysis of variance or the t-test for continuous variables, and the chi-square test for categorical variables. Statistical significance was set at p < 0.05LDL-C Low-density lipoprotein cholesterol, TC Total cholesterol, TG Triglyceride, HDL-C High-density lipoprotein cholesterol, APOE Blood APOE concentration, WBC Leukocyte, NEU Neutrophil, LYM Lymphocyte, PLT Platelet Baseline characteristics of participants in the different APOE alleles Continuous variables were expressed as mean (M) with standard deviation (SD), and categorical variables were expressed as proportions. Differences were evaluated using the analysis of variance or the t-test for continuous variables, and the chi-square test for categorical variables. Statistical significance was set at p < 0.05 LDL-C Low-density lipoprotein cholesterol, TC Total cholesterol, TG Triglyceride, HDL-C High-density lipoprotein cholesterol, APOE Blood APOE concentration, WBC Leukocyte, NEU Neutrophil, LYM Lymphocyte, PLT Platelet Relationship between APOE genotype and SII Table 2 presents the results of linear regression analyses examining the association between the APOE genotype and Systemic Immune-Inflammation Index (SII), utilizing three progressively adjusted models. Model 1 (Crude Model) was unadjusted, and the initial association between the APOE genotype and SII was evaluated. Model 2 (Partially Adjusted Model) was controlled for demographic and lifestyle factors including sex, age, smoking, and alcohol consumption. Model 3 (Fully Adjusted Model) was additionally adjusted for clinical comorbidities (hypertension, cardiovascular disease, diabetes, and cerebral stroke) to mitigate potential confounding factors and estimate the independent effect of the APOE genotype on SII. Consistent with all the models, ɛ2 alleles were significantly associated with lower SII levels (Model 3: β=-0.077, 95% CI: -0.096 to -0.058, p < 0.05), whereas ɛ4 alleles were associated with higher SII levels (Model 3: β = 0.059, 95% CI: 0.041–0.077, p < 0.05). Table 2Relationship between APOE genotype and SIICrude Model(Model 1)Partially Adjusted Model(Model 2)Fully Adjusted Model(Model 3)β (95% CI) p-Valueβ (95% CI) p-Valueβ (95% CI) p-ValueE3ReferenceReferenceReferenceE2-0.077(-0.096, -0.058) *-0.077(-0.096, -0.058) *-0.077(-0.096, -0.058) *E40.064(0.046, 0.082) *0.063(0.045, 0.081) *0.059(0.041, 0.077) *Model 1: No covariates were adjusted. Model 2 was adjusted for sex, age, smoking status, and alcohol consumption status. Model 3 was adjusted for sex, age, smoking status, alcohol consumption status, hypertension, cardiovascular disease, diabetes, and cerebral stroke. 95% CI, 95% confidence interval; β, regression coefficients β. p < 0.05, considered statistically significant. The “*” symbol indicates that the results were significant Table 2Relationship between APOE genotype and SIICrude Model(Model 1)Partially Adjusted Model(Model 2)Fully Adjusted Model(Model 3)β (95% CI) p-Valueβ (95% CI) p-Valueβ (95% CI) p-ValueE3ReferenceReferenceReferenceE2-0.077(-0.096, -0.058) *-0.077(-0.096, -0.058) *-0.077(-0.096, -0.058) *E40.064(0.046, 0.082) *0.063(0.045, 0.081) *0.059(0.041, 0.077) *Model 1: No covariates were adjusted. Model 2 was adjusted for sex, age, smoking status, and alcohol consumption status. Model 3 was adjusted for sex, age, smoking status, alcohol consumption status, hypertension, cardiovascular disease, diabetes, and cerebral stroke. 95% CI, 95% confidence interval; β, regression coefficients β. p < 0.05, considered statistically significant. The “*” symbol indicates that the results were significant Relationship between APOE genotype and SII Model 1: No covariates were adjusted. Model 2 was adjusted for sex, age, smoking status, and alcohol consumption status. Model 3 was adjusted for sex, age, smoking status, alcohol consumption status, hypertension, cardiovascular disease, diabetes, and cerebral stroke. 95% CI, 95% confidence interval; β, regression coefficients β. p < 0.05, considered statistically significant. The “*” symbol indicates that the results were significant Subgroup analysis Further subgroup analysis revealed that the association between SII and APOE genotypes was consistent, as shown in Fig. 2. The SII correlated significantly with the APOE gene in subgroups stratified by sex, age, hypertension, and diabetes (p < 0.05). Interaction tests revealed that the relationship between APOE genotypes and SII was not statistically different across strata, indicating that age, sex, hypertension, and diabetes did not significantly affect this positive correlation (p > 0.05). Fig. 2Subgroup analysis Subgroup analysis Relationship between APOE genotype and Hs-CRP/SII Linear regression analyses stratified by inflammatory biomarkers (Table 3) revealed divergent associations between the APOE genotypes and systemic inflammation. ɛ2 allele carriers were significantly associated with lower SII levels whereas ɛ4 allele carriers were associated with higher SII levels. Conversely, for Hs-CRP, ɛ4 allele carriers were lower than ɛ3 allele carriers (Model 3: β=-0.193, 95%CI -0.227 to -0.160, p < 0.05), whereas ɛ2 allele carriers were higher in the fully adjusted model (Model 3: β = 0.043, 95% CI 0.008 to 0.078; p < 0.05). Table 3Relationship between APOE genotype and Hs-CRP/SIICrude Model(Model 1)Partially Adjusted Model(Model 2)Fully Adjusted Model(Model 3)β (95% CI) p-Valueβ (95% CI) p-Valueβ (95% CI) p-ValueSII E3ReferenceReferenceReference E2-0.077(-0.096, -0.058) *-0.077(-0.096, -0.058) *-0.077(-0.096, -0.058) * E40.064(0.046, 0.082) *0.063(0.045, 0.081) *0.059(0.041, 0.077) *Hs-CRP E3ReferenceReferenceReference E20.039(0.004, 0.074) *0.041(0.006, 0.076) *0.043(0.008, 0.078) * E4-0.187(-0.221, -0.154) *-0.184(-0.217, -0.151) *-0.193(-0.227, -0.160) *Model 1: No covariates were adjusted. Model 2 was adjusted for sex, age, smoking status, and alcohol consumption status. Model 3 was adjusted for sex, age, smoking status, alcohol consumption status, hypertension, cardiovascular disease, diabetes, and cerebral stroke. 95% CI, 95% confidence interval; β, regression coefficients β. p < 0.05, considered statistically significant. The “*” symbol indicates that the results were significantSII Systemic immune-inflammation index, Hs-CRP High-sensitivity C-reactive protein Table 3Relationship between APOE genotype and Hs-CRP/SIICrude Model(Model 1)Partially Adjusted Model(Model 2)Fully Adjusted Model(Model 3)β (95% CI) p-Valueβ (95% CI) p-Valueβ (95% CI) p-ValueSII E3ReferenceReferenceReference E2-0.077(-0.096, -0.058) *-0.077(-0.096, -0.058) *-0.077(-0.096, -0.058) * E40.064(0.046, 0.082) *0.063(0.045, 0.081) *0.059(0.041, 0.077) *Hs-CRP E3ReferenceReferenceReference E20.039(0.004, 0.074) *0.041(0.006, 0.076) *0.043(0.008, 0.078) * E4-0.187(-0.221, -0.154) *-0.184(-0.217, -0.151) *-0.193(-0.227, -0.160) *Model 1: No covariates were adjusted. Model 2 was adjusted for sex, age, smoking status, and alcohol consumption status. Model 3 was adjusted for sex, age, smoking status, alcohol consumption status, hypertension, cardiovascular disease, diabetes, and cerebral stroke. 95% CI, 95% confidence interval; β, regression coefficients β. p < 0.05, considered statistically significant. The “*” symbol indicates that the results were significantSII Systemic immune-inflammation index, Hs-CRP High-sensitivity C-reactive protein Relationship between APOE genotype and Hs-CRP/SII Model 1: No covariates were adjusted. Model 2 was adjusted for sex, age, smoking status, and alcohol consumption status. Model 3 was adjusted for sex, age, smoking status, alcohol consumption status, hypertension, cardiovascular disease, diabetes, and cerebral stroke. 95% CI, 95% confidence interval; β, regression coefficients β. p < 0.05, considered statistically significant. The “*” symbol indicates that the results were significant SII Systemic immune-inflammation index, Hs-CRP High-sensitivity C-reactive protein Discussion This study observed a significant association between the APOE genotype and SII, in which APOE ε4 allele carriers had significantly higher SII levels than APOE ε3 allele carriers, whereas APOE ε2 allele carriers had lower SII levels. This finding reveals a new dimension of APOE allele in regulating systemic inflammatory status, and it is noteworthy that this distribution pattern of SII is inconsistent with the pattern of Hs-CRP levels observed in the same population. An in-depth discussion of the results is as follows. APOE ε4 and enhanced inflammatory status APOE ε4 carriers in this study showed the highest SII levels, which is consistent with the pro-inflammatory properties of APOE ε4 reported in numerous studies [1, 5, 8]. APOE ε4 protein is considered structurally unstable and functionally abnormal [9], and its structural changes may affect its binding to lipoproteins and cell receptors, leading to disordered cholesterol metabolism and abnormal deposition of lipids in blood vessels and the brain [10]. A sustained inflammatory response is now regarded as a fundamental pathological process underlying all phases of atherosclerosis [11]. These processes triggers and sustains inflammatory responses by activating endothelial cells and macrophages. In addition, evidence shows that APOE ε4 protein may be more likely to activate pro-inflammatory signaling pathways [1] or have a weaker response to inflammatory resolution signals. APOE ε4 is associated with impaired mitochondrial function [12] and increased oxidative stress [13], both of which are important drivers of inflammation. SII integrates neutrophil, lymphocyte, and platelet counts [7]. Neutrophils are key effector cells of acute inflammation. Lymphopenia is often associated with chronic inflammation and stress, and platelet activation is involved in inflammation and thrombosis. Therefore, high SII reflects a systemic inflammatory and immune activation state dominated by neutrophil and platelet activation, accompanied by relative lymphopenia [7]. The high SII in APOE ε4 carriers suggests that their basal immune environment tends to be in such a pro-inflammatory and pro-thrombotic state. APOE ε2 and potential Anti-Inflammatory protective effects This study observed that APOE ε2 carriers had the lowest SII levels, providing new supporting evidence for the view that APOE ε2 may have anti-inflammatory or immunomodulatory effects [14]. Although the APOE ε2 allele confers a well-established protective effect against Alzheimer’s disease and has been linked to extended lifespan [15], it paradoxically represents a major genetic risk factor for type III hyperlipoproteinemia and associated hypertriglyceridemia [16]. These opposing phenotypic associations suggest that the neuroprotective benefits of the ε2 allele may be attributable, at least in part, to its distinct anti-inflammatory properties, which could offset its adverse metabolic consequences related to impaired lipoprotein clearance [15]. Some studies have shown that APOE ε2 may have stronger antioxidant capacity, possibly affecting the inflammatory response pattern of macrophages and microglia and promoting their transformation into an anti-inflammatory or repair phenotype. APOE ε2 exhibits reduced susceptibility to neuronal recognition as an aberrant protein conformation, thereby minimizing the generation of neurotoxic fragments capable of triggering inflammatory cascades [17]. Supplementation with exogenous APOE ε2 protein has been shown to mitigate Aβ plaque burden, attenuate neurodegenerative synaptic pruning, and consequently ameliorate neuroinflammatory cascades [18]. Low SII values are generally considered to reflect a relatively low systemic inflammatory load and a more balanced immune status. Reduced inflammation levels may underlie the longevity observed in the APOE ε2 allele, as reflected by the low SII of these carriers – suggesting a systemic immune environment conducive to homeostasis, anti-inflammatory responses, and immune tolerance [19]. Inconsistency between SII and Hs-CRP distribution This is the most striking finding of this study, and needs to be discussed emphatically. Hs-CRP is an acute-phase protein produced by the liver, mainly regulated by IL-6, reflecting relatively “acute” or “systemic” inflammatory stimuli [20]. Previous studies have shown that APOE ε2 carriers has higher Hs-CRP [21], and APOE ε4 carriers has lower Hs-CRP [5, 22]. SII is calculated from peripheral blood leukocyte and platelet counts, serving as a dynamic biomarker that integrates real-time homeostasis of circulating innate immune cells, adaptive immune cells, and platelets—key mediators of inflammation-coagulation crosstalk [7]. APOE ε4 acts not only within the realm of lipid metabolism but also as an active immunomodulatory driver. It triggers a chronic, low-grade, cell-mediated inflammation within both the cerebrovascular unit—leading to endothelial dysfunction, blood-brain barrier disruption, and peripheral immune cell infiltration—and the brain parenchyma, resulting in microglial dysfunction, impaired clearance, and a shift toward a pro-inflammatory phenotype [23, 24]. This process establishes a persistent toxic microenvironment that fuels core neurodegenerative pathology. This tissue-specific inflammatory response exerts systemic immunological effects. Consequently, its signal is more prominent and direct in SII than in the relatively static, single-molecule marker Hs-CRP, which primarily reflects hepatic acute-phase reactions [25]. This distinction reveals that these biomarkers capture fundamentally different biological dimensions: Hs-CRP indicates the terminal output of systemic cytokine storms, whereas SII quantifies in real-time the composition and status of effector cells involved in chronic inflammation. These findings align closely with and mechanistically extend the “inflammaging” framework [26]. APOE ε4 can be viewed as an accelerator, predisposing carriers to an earlier and more pronounced trajectory of age-related immune dysregulation [6]. This trajectory is characterized by innate immune hyperactivation (reflected by elevated neutrophils in SII) coupled with adaptive immune decline (marked by reduced lymphocytes in SII). Therefore, an elevated SII is not merely an inflammatory marker but a quantifiable signature of systemic immunosenescence and exhaustion, signifying a shift in peripheral immune homeostasis toward a pro-inflammatory state [27]. Clinical significance and future directions Our findings establish SII as a unique composite biomarker capable of delineating APOE genotype-specific immune-inflammatory phenotypes that are distinct from Hs-CRP. Persistently elevated SII in APOE ε4 carriers reflects a chronic pro-inflammatory milieu characterized by innate immune activation and pre-thrombotic states, constituting a key mechanism for their heightened susceptibility to neurodegenerative and vascular pathologies. Conversely, APOE ε2-associated low SII substantiates systemic anti-inflammatory protection, potentially explaining its cardioprotective and Alzheimer’s disease-mitigating effects. SII has emerged as a validated biomarker for risk stratification in rheumatoid arthritis [28], heart failure [29], osteoporosis [30], and cardiovascular diseases [31], while also demonstrating prognostic utility in oncology [32]. Future research must implement longitudinal studies correlating SII dynamics, APOE genotypes, and disease progression including cognitive decline and cardiovascular events; mechanistically interrogate how APOE isoforms regulate immune cell subpopulations—neutrophils, monocytes, lymphocytes—platelet function, and cellular crosstalk; and validate findings through multi-inflammatory marker profiling such as cytokines IL-1β/IL-6/TNF-α/IL-10, chemokines, and soluble receptors to comprehensively map APOE-driven immunoinflammatory networks and clarify SII-Hs-CRP divergence pathways. Ultimately, targeted anti-inflammatory approaches that inhibit neutrophil activation or platelet-leukocyte interactions should be explored to mitigate APOE ε4 carriers’ elevated disease risk. Study limitations This study had a cross-sectional design and could not determine causal relationships. SII and Hs-CRP levels may be affected by multiple confounding factors (such as recent infections, medications, and other chronic diseases). Although we tried our best to control for these factors, residual confounding factors may still exist. No other important inflammatory cytokines or immune cell functions were detected. Conclusion APOE plays a pivotal role in immune regulation by differentially modulating the innate and adaptive arms of the immune system. However, this immunomodulatory function can become dysregulated, particularly with the APOE ε4 allele, leading to a failure to resolve acute inflammatory responses. Consequently, a state of chronic low-grade inflammation is established. This persistent inflammatory tone is now widely recognized as a key mechanistic pathway through which APOE ultimately contributes to an elevated risk for a spectrum of diseases, including neurodegenerative and cardiovascular disorders.